Crinetics Pharmaceuticals (CRNX) EBITDA (2017 - 2026)
Crinetics Pharmaceuticals' quarterly EBITDA came in at -$131.0 million in Q1 2026, down 36.8% year-on-year from -$207.2 million in Q1 2025, and down 6.35% quarter-over-quarter from -$123.1 million in Q4 2025.
Crinetics Pharmaceuticals has reported EBITDA for 10 years, with the latest figure at -$131.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 36.8% year-over-year to -$131.0 million; the trailing twelve-month figure through Mar 2026 stood at -$499.6 million (down 53.08% YoY), and the FY2025 full-year result was -$464.4 million, down 55.62% from the prior year.
- EBITDA for Q1 2026 stood at -$131.0 million, down from -$123.1 million in the prior quarter.
- The five-year high for EBITDA was -$36.4 million in Q1 2022, with the low at -$131.0 million in Q1 2026.
- Average EBITDA over 5 years is -$74.8 million, with a median of -$67.8 million recorded in 2024.
- Year-over-year, EBITDA fell 14.54% in 2023 and tumbled 73.62% in 2025.
- Tracing CRNX's EBITDA over 5 years: stood at -$43.9 million in 2022, then plunged by 32.66% to -$58.3 million in 2023, then plunged by 40.19% to -$81.7 million in 2024, then tumbled by 50.78% to -$123.1 million in 2025, then fell by 6.35% to -$131.0 million in 2026.
- The last three EBITDA figures came in at -$131.0 million (Q1 2026), -$123.1 million (Q4 2025), and -$129.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | -130.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -130.96 Mn |
| Dec 31, 2025 | -123.14 Mn |
| Sep 30, 2025 | -129.52 Mn |
| Jun 30, 2025 | -116.02 Mn |
| Mar 31, 2025 | -95.74 Mn |
| Dec 31, 2024 | -81.67 Mn |
| Sep 30, 2024 | -74.60 Mn |
| Jun 30, 2024 | -74.40 Mn |
| Mar 31, 2024 | -67.76 Mn |
| Dec 31, 2023 | -58.26 Mn |
| Sep 30, 2023 | -56.62 Mn |
| Jun 30, 2023 | -50.17 Mn |
| Mar 31, 2023 | -44.58 Mn |
| Dec 31, 2022 | -43.91 Mn |
| Sep 30, 2022 | -43.32 Mn |
| Jun 30, 2022 | -43.80 Mn |
| Mar 31, 2022 | -36.44 Mn |
| Dec 31, 2021 | -31.16 Mn |
| Sep 30, 2021 | -27.87 Mn |
| Jun 30, 2021 | -26.10 Mn |
| Mar 31, 2021 | -22.91 Mn |
| Dec 31, 2020 | -21.66 Mn |
| Sep 30, 2020 | -18.40 Mn |
| Jun 30, 2020 | -16.53 Mn |
| Mar 31, 2020 | -17.34 Mn |
| Dec 31, 2019 | -14.60 Mn |
| Sep 30, 2019 | -14.47 Mn |
| Jun 30, 2019 | -12.34 Mn |
| Mar 31, 2019 | -8.93 Mn |
| Dec 31, 2018 | -8.43 Mn |
| Sep 30, 2018 | -7.59 Mn |
| Jun 30, 2018 | -5.57 Mn |
| Mar 31, 2018 | -5.46 Mn |
| Dec 31, 2017 | -2.50 Mn |
| Sep 30, 2017 | -2.37 Mn |
| Jun 30, 2017 | -1.64 Mn |